FULL DISCLOSURE: Cardiol Therapeutics is a sponsor of theDeepDive.ca.
In this interview David Elsley, CEO of Cardiol Therapeutics (NASDAQ: CRDL) (TSXV: CRDL), shares some compelling clinical data that could be a real game-changer for treating dangerous heart swelling. The research focuses on addressing early warning signs that are connected to serious cardiac conditions, which could make a meaningful difference for patient outcomes.
The conversation dives into how their approach might offer safer treatment paths for patients struggling with recurring heart inflammation, which can be incredibly painful and debilitating. David gives a clear picture of where this research stands and what it could mean for people facing these serious cardiac challenges.
FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.
